Satish Jha co-wrote this blog post with Vishal Kabra
Today, there is no denying that when it comes to increasing efficiency, reducing cost and offering a better customer experience, intelligent process automation (IPA) is a go-to strategy for businesses, and pharma is no exception. IPA promises that it can free up people to do more value-added work and play more strategic roles within their organizations. At a fundamental level, IPA is an emerging set of new technologies that include robotic process automation (RPA), conversational AI and machine learning to mimic activities carried out by humans. With the evolution in IPA technologies and the broad applicability of such automation, IPA continues to be a buzzword in every industry. Given the many benefits and possibilities, it’s understandable why organizations are jumping onto the IPA bandwagon.
However, most organizations aren’t succeeding at scaling intelligent process automation.